Design of the hPD-1/hLAG3 mouse

The double-humanized PD‑1 and LAG3 (hPD-1/hLAG3) mouse model was generated by intercrossing hPD-1 and hLAG3 mice.

The PD-1 humanized model, developed by Knockin at the mouse Pd‑1 locus, expresses a chimeric PD‑1: human extracellular and mouse transmembrane and intracellular domains.

The LAG3 humanized model, developed by Knockin at the mouse Lag3 locus, expresses the full-length chimeric LAG3 isoform (human extracellular domains, and mouse transmembrane and intracellular domains).

Both hPD-1 and hLAG3 expressions are regulated by endogenous mouse promoters.

hPD-1/hLAG3 features

  • PD-1 and LAG3 extracellular domains are entirely humanized
  • hPD-1 and hLAG3 expression driven by the respective endogenous mouse promoter
  • Fully functional mouse immune system
  • Lack of expression of the murine target gene, thus avoiding cross-reactivity

Validation

Related ressources et publications

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No results

Discover related products to

hPD-1/hLAG3

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Mouse
ICP
PD-1
GITR
ICP (multi-target)

hPD-1/hGITR/hGITRL

The hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

Mouse
ICP
VISTA
ICP (single-target)

hVISTA

The hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint VISTA in fully immunocompetent mice.

Mouse
ICP
STING
ICP (single-target)

hSTING

The hSTING mouse enables the in vivo assessment of agents and therapies targeting  the human immune checkpoint STING in fully immunocompetent mice.

Mouse
ICP
OX40
ICP (single-target)

hOX40

The hOX40 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint OX40 in fully immunocompetent mice.

Mouse
ICP
GITR
ICP (single-target)

hGITR

The hGITR mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR in fully immunocompetent mice.

Mouse
ICP
CTLA-4
ICP (single-target)

hCTLA-4

The hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 in fully immunocompetent mice.

Mouse
ICP
CD39
ICP (single-target)

hCD39

The hCD39 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD39 in fully immunocompetent mice.

Mouse
ICP
CD28
ICP (single-target)

hCD28

The hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.

Mouse
ICP
PD-1
PD-L1
ICP (multi-target)

hPD-1/hPD-L1

The hPD-1/hPD-L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice.

Mouse
ICP
PD-1
VISTA
ICP (multi-target)

hPD-1/hVISTA

The hPD-1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

Mouse
ICP
PD-1
TIM3
ICP (multi-target)

hPD-1/hTIM3

The hPD-1/hTIM3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or TIM3 in fully immunocompetent mice.

Mouse
ICP
Reporter
GITR
Foxp3

hGITR/Foxp3

The hGITR/Foxp3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR. The red fluorescent protein regulated under the Foxp3 promoter allows you to efficiently monitor and sort Foxp3-expressing cells from different lymphocyte lineages and lymphoid organs.in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice.

Mouse
ICP
GITR
GITRL
ICP (multi-target)

hGITR/hGITRL

The hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of agonist and antagonist antibodies targeting human immune checkpoint GITR and/or GITRL in fully immunocompetent mice.

Mouse
ICP
CTLA-4
PD-1
ICP (multi-target)

hPD-1/hCTLA-4

The hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice.

Mouse
ICP
CTLA-4
Lag3
ICP (multi-target)

hCTLA-4/hLAG3

The hCTLA-4/hLAG3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 and/or LAG3 in fully immunocompetent mice.

Cells
PD-L1
ICP
MC38
PD-1

MC38-hPD-L1-LZ

The MC38-hPD-L1-LZ clonal cell line expresses high levels of  human PD-L1 and forms solid tumors in vivo. An optimized version of a  luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

Mouse
PD-1
ICP
ICP (single-target)

hPD-1

The hPD-1 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 in fully immunocompetent mice.

Preclinical double-humanized PD-1/LAG3 mouse model

Get in touch about

Let us know how we can help

In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.

From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.